Burzynski Research Institute (BZYR) Income from Continuing Operations (2010 - 2025)
Burzynski Research Institute (BZYR) posted Income from Continuing Operations of 190196.0 for Q4 2025, up 27.89% sequentially from 263755.0 in Q3 2025, and up 31.65% YoY from 144470.61 in Q4 2024.
Burzynski Research Institute (BZYR) Income from Continuing Operations (2010 - 2025) Analysis & Trends
Burzynski Research Institute has reported Income from Continuing Operations for 16 years, with the latest figure at 190196.0 in Q4 2025.
- Quarterly Income from Continuing Operations rose 31.65% year-over-year to 190196.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was 1078200.0 (up 11.61% YoY) and the FY2025 annual result came in at 1386207.0, down 3.99% from the prior year.
- Income from Continuing Operations climbed to 190196.0 in Q4 2025 per BZYR's latest filing, from 263755.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 153163.0 in Q1 2021 and troughed at 433015.0 in Q4 2023.
- A 5-year average of 263404.95 and a median of 264265.5 in 2021 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2021 and 2023: Income from Continuing Operations soared 46.12% in 2021, then slumped 71.4% in 2023.
- Over 5 years, Income from Continuing Operations stood at 264776.0 in 2021, then gained by 4.58% to 252639.0 in 2022, then plunged by 71.4% to 433015.0 in 2023, then surged by 35.74% to 278269.0 in 2024, then soared by 31.65% to 190196.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 190196.0, 263755.0, and 331451.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | -190,196.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | -190,196.00 |
| Aug 31, 2025 | -263,755.00 |
| May 31, 2025 | -331,451.00 |
| Feb 28, 2025 | -292,798.00 |
| Nov 30, 2024 | -278,269.00 |
| Aug 31, 2024 | -292,172.00 |
| May 31, 2024 | -293,352.00 |
| Feb 29, 2024 | -356,080.00 |
| Nov 30, 2023 | -433,015.00 |
| Aug 31, 2023 | -265,973.00 |
| May 31, 2023 | -227,050.00 |
| Feb 28, 2023 | -219,134.00 |
| Nov 30, 2022 | -252,639.00 |
| Aug 31, 2022 | -210,659.00 |
| May 31, 2022 | -231,737.00 |
| Feb 28, 2022 | -170,879.00 |
| Nov 30, 2021 | -264,776.00 |
| Aug 31, 2021 | -224,718.00 |
| May 31, 2021 | -316,283.00 |
| Feb 28, 2021 | -153,163.00 |